Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: William F. Wager, Jr. who wrote (1190)	4/21/1999 10:59:00 AM
From: muddphudd	Read Replies (1) \| Respond to of 1580

Thanks. That is what I was looking for. I saw a similar article on prnewswire: "Although the Committee recommended that the prescribing information include the standard gastrointestinal (GI) warning for nonsteroidal anti-inflammatory drugs (NSAIDs), the Committee agreed that the labeling include a statement that the GI safety profile of Vioxx 25 mg differs significantly from ibuprofen, a widely prescribed NSAID. In this context, investigational anti-inflammatory and analgesic medications such as Vioxx, also known as COX-2 specific inhibitors, are being evaluated in clinical studies to determine whether the difference in how they work may result in fewer gastrointestinal side effects than traditional NSAIDs, such as ibuprofen."